Aureus Asset Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Aureus Asset Management’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,511	Closed	-$16.2K	–	213
2023 Q4	$16.2K	Hold	1,511	–	–	﹤0.01%	196
2023 Q3	$9.06K	Hold	1,511	–	–	﹤0.01%	193
2023 Q2	$10.4K	Hold	1,511	–	–	﹤0.01%	185
2023 Q1	$23.7K	Hold	1,511	–	–	﹤0.01%	180
2022 Q4	$30.2K	Hold	1,511	–	–	﹤0.01%	174
2022 Q3	$27K	Hold	1,511	–	–	﹤0.01%	166
2022 Q2	$34K	Hold	1,511	–	–	﹤0.01%	183
2022 Q1	$42K	Hold	1,511	–	–	﹤0.01%	213
2021 Q4	$69K	Hold	1,511	–	–	﹤0.01%	206
2021 Q3	$126K	Hold	1,511	–	–	0.01%	205
2021 Q2	$144K	Hold	1,511	–	–	0.01%	225
2021 Q1	$251K	Sell	1,511 -2,000	-57%	-$265K	0.02%	154
2020 Q4	$344K	Hold	3,511	–	–	0.03%	144
2020 Q3	$119K	Hold	3,511	–	–	0.01%	173
2020 Q2	$199K	Hold	3,511	–	–	0.02%	164
2020 Q1	$206K	Hold	3,511	–	–	0.03%	141
2019 Q4	$277K	Hold	3,511	–	–	0.03%	152
2019 Q3	$351K	Hold	3,511	–	–	0.04%	125
2019 Q2	$468K	Buy	+3,511	New	+$542K	0.06%	111

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aureus Asset Management's ONCT Position: Q1 2024 in Review

Aureus Asset Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 1,511 shares — an estimated $16.2K sold.

Aureus Asset Management first reported a position in ONCT in Q2 2019 and held it in 19 quarters. The position peaked at $468K in Q2 2019. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

Aureus Asset Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Aureus Asset Management sold 1,511 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $16.2K.
Aureus Asset Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
Aureus Asset Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $468K in Q2 2019.
24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Aureus Asset Management's 13F filing for Q1 2024, filed 13 May 2024.